

USER GUIDE

invitrogen™
by *life* technologies™

pcDNA™4/HisMax A, B, and C

Catalog number V864-20

Revision date 8 November 2011

Publication Part number 25-0258

MAN0000096

For Research Use Only. Not for diagnostic procedures.

life
technologies™

Table of Contents

General Information	iv
Methods	1
Overview	1
Accessory Products	2
Cloning into pcDNA™ 4/HisMax A, B, and C	3
Transfection and Analysis	9
Creation of Stable Cell Lines	12
Appendix	16
pcDNA™4/HisMax Vector	16
pcDNA™ 4/HisMax/lacZ	18
Technical Support	19
Purchaser Notification	20
References	21

General Information

Contents 20 µg each pcDNA[™]4/HisMax A, B, and C, lyophilized in TE, pH 8.0
20 µg pcDNA[™]4/HisMax/*lacZ*, lyophilized in TE, pH 8.0

Shipping/Storage Lyophilized plasmids are shipped at room temperature and stored at -20°C.

Product Use **For research use only.** Not intended for any human or animal diagnostic or therapeutic uses.

Methods

Overview

Introduction

pcDNA[™] 4/HisMax A, B, and C are 5.3 kb vectors derived from pcDNA[™] 4/His and designed for overproduction of recombinant proteins in mammalian cell lines. Features of the vectors allow purification and detection of expressed proteins (see pages 16-17 for more information). High-level stable and transient expression can be carried out in most mammalian cells. The vectors contain the following elements:

- Human cytomegalovirus immediate-early (CMV) promoter for high-level expression in a wide range of mammalian cells
- QBI SP163 translational enhancer for increased levels of recombinant protein expression (Stein *et al.*, 1998) (see page 4 for more information)
- Three reading frames to facilitate in-frame cloning with an N-terminal peptide encoding the Xpress[™] epitope and a polyhistidine metal-binding tag
- Zeocin[™] resistance gene for selection of stable cell lines (Mulsant *et al.*, 1988) (see page 12 for more information)
- Episomal replication in cell lines that are latently infected with SV40 or that express the SV40 large T antigen (e.g. COS-1, COS-7)

The control plasmid, pcDNA[™] 4/HisMax/*lacZ*, is included for use as a positive control for transfection, expression, and detection in the cell line of choice.

Experimental Outline

Use the following outline to clone and express your gene of interest in pcDNA[™] 4/HisMax.

- Consult the multiple cloning sites described on pages 5-7 to determine which vector (A, B, or C) should be used to clone your gene in frame with the N-terminal Xpress[™] epitope and the polyhistidine tag.
 - Ligate your insert into the appropriate vector and transform into *E. coli*. Select transformants on 50 to 100 µg/ml ampicillin or 25-50 µg/ml Zeocin[™].
 - Analyze your transformants for the presence of insert by restriction digestion.
 - Select a transformant with the correct restriction pattern and use sequencing to confirm that your gene is cloned in frame with the N-terminal peptide.
 - Transfect your construct into the cell line of choice using your own method of transfection. Generate a stable cell line, if desired.
 - Test for expression of your recombinant gene by western blot analysis or functional assay. For antibody to the Xpress[™] epitope, please see the next page.
 - To purify your recombinant protein, you may use metal-chelating resin such as ProBond[™]. ProBond[™] resin is available separately (see next page for ordering information).
-

Accessory Products

Introduction

The products listed below are designed to help you detect and purify your recombinant fusion protein expressed from pcDNATM 4/HisMax. In addition, Life Technologies has a wide variety of mammalian expression vectors, many of which can be utilized with pcDNATM 4/HisMax to express and detect multiple proteins in the same cell (see below).

Antibodies for Detection

If you do not have an antibody to your protein, Life Technologies offers the Anti-XpressTM antibodies and Anti-HisG antibodies to detect your recombinant fusion protein. For more information, please refer to our website (www.lifetechnologies.com) or call Technical Support (see page 19).

ProBondTM Resin

Ordering information for ProBondTM resin is provided below.

Item	Amount	Catalog no.
ProBond TM Purification System	6 x 2 ml precharged, prepacked ProBond TM resin columns and buffers for native and denaturing purification	K850-01
ProBond TM Purification System with Anti-Xpress TM Antibody	1 kit	K851-01
ProBond TM Resin	50 ml	R801-01
	150 ml	R801-15

Expression Vectors

We have a wide variety of mammalian expression vectors utilizing the CMV or EF-1 α promoter. Vectors are available with the XpressTM (N-terminal), *c-myc* (C-terminal), or V5 (C-terminal) epitope for detection and either the neomycin, blasticidin, or ZeocinTM resistance genes. All vectors utilize the polyhistidine tag for purification using ProBondTM resin. For more information on the mammalian expression vectors available, please see our website (www.lifetechnologies.com) or call Technical Support (see page 19).

Cloning into pcDNA[™] 4/HisMax A, B, and C

Introduction

Diagrams are provided on pages 5-7 to help you ligate your gene of interest in frame with the N-terminal peptide. General considerations for cloning and transformation are listed below.

General Molecular Biology Techniques

For help with DNA ligations, *E. coli* transformations, restriction enzyme analysis, DNA sequencing, and DNA biochemistry, please refer to *Molecular Cloning: A Laboratory Manual* (Sambrook *et al.*, 1989) or *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

E. coli Strain

Many *E. coli* strains are suitable for the propagation of this vector. We recommend that you propagate vectors containing inserts in *E. coli* strains that are recombination deficient (*recA*) and endonuclease A deficient (*endA*).

For your convenience, TOP10F' is available as chemically competent or electrocompetent cells from Life Technologies.

Item	Quantity	Catalog no.
Electrocomp [™] TOP10F'	5 x 80 µl	C665-55
One Shot [®] TOP10F' (chemically competent cells)	21 x 50 µl	C3030-03

Transformation Method

You may use any method of your choice for transformation. Chemical transformation is the most convenient for most researchers. Electroporation is the most efficient and the method of choice for large plasmids.

Maintenance of pcDNA[™] 4/HisMax

To propagate and maintain the pcDNA[™] 4/HisMax vectors, we recommend resuspending each vector in 20 µl sterile water to prepare a 1 µg/µl stock solution. Store the stock solution at -20°C.

Use this stock solution to transform a *recA*, *endA* *E. coli* strain like TOP10F', DH5α[™], JM109, or equivalent. Select transformants on LB plates containing 50 to 100 µg/ml ampicillin or 25 to 50 µg/ml Zeocin[™] in Low Salt LB. Be sure to prepare a glycerol stock of each plasmid for long-term storage (see page 8 for protocol).

continued on next page

Cloning into pcDNA[™] 4/HisMax A, B, and C, continued

QBI SP163 Translational Enhancer

The QBI SP163 element is a 163 nucleotide splice variant derived from the 5' untranslated region (UTR) of the mouse vascular endothelial growth factor (VEGF) gene (Stein *et al.*, 1998). The splice variant is composed of a 31 nucleotide fragment containing the 5' cap sequence of the VEGF gene fused to a 132 nucleotide fragment of the 5' UTR immediately preceding the translational start site of the VEGF gene. Please refer to the diagrams on pages 5-7 for the sequence of the QBI SP163 element.

The QBI SP163 element functions as a strong translational enhancer and acts to increase recombinant protein production when placed directly upstream of the ATG initiation codon of the gene of interest. The increase in protein expression is thought to occur through ribosome recruitment and a cap-independent translation mechanism. (Stein *et al.*, 1998).

In general, expression levels of recombinant protein from pcDNA[™] 4/HisMax are 2-5 fold greater than the levels obtained with the pcDNA[™] 4/His expression vector. The amount of recombinant protein expressed will vary depending on the nature of the gene of interest.

Note

The pcDNA[™] 4/HisMax vectors are fusion vectors. To ensure proper expression of your recombinant protein, you must clone your gene in frame with the ATG at base pairs 1080-1082. This will create a fusion with the N-terminal polyhistidine tag, Xpress[™] epitope, and the enterokinase cleavage site. The vector is supplied with the multiple cloning site in three reading frames relative to the N-terminal peptide to facilitate cloning. See pages 5-7 to develop a cloning strategy.

If you wish to clone your gene as close as possible to the enterokinase cleavage site, follow the guidelines below:

- Digest pcDNA[™] 4/HisMax A, B, or C with *Kpn* I.
- Create blunt ends with T4 DNA polymerase and dNTPs.
- Clone your blunt-ended insert in frame with the lysine codon (AAG) of the enterokinase recognition site.

If you wish to separate your protein of interest from the N-terminal peptide tag, you may use any suitable enterokinase including EnterokinaseMax[™] (EKMax[™], Catalog no. E180-01) from Life Technologies. Following enterokinase cleavage, no vector-encoded amino acid residues will be present in your protein.

continued on next page

Cloning into pcDNATM 4/HisMax A, B, and C, continued

Multiple Cloning Site of Version A

Below is the multiple cloning site for pcDNATM 4/HisMax A. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotides indicate the variable region. **Please note that there is a stop codon within the Xba I site.** The multiple cloning site has been confirmed by sequencing and functional testing. **The complete sequence of pcDNATM 4/HisMax A is available for downloading from our website (www.lifetechnologies.com) or from Technical Support (see page 19).**

```

821 CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG
                                     T7 promoter/priming site
881 GGAGACCCAA GCTGGCTAGC GTTTAAACTT AAGCTTAGCG CAGAGGCTTG GGGCAGCCGA
                                     QBI SP163 translational enhancer
941 GCGGCAGCCA GGCCCCGGCC CGGGCCTCGG TTCCAGAAGG GAGAGGAGCC CGCCAAGGCC
1001 CGCAAGAGAG CGGGCTGCCT CGCAGTCCGA GCCGGAGAGG GAGCGCGAGC CGCGCCGGCC
1061 CCGGACGGCC TCCGAAACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT
    Met Gly Gly Ser His His His His His His His
                                     Polyhistidine Region
1110 GGT ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC
    Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr
                                     XpressTM Epitope
1158 GAC GAT GAC GAT AAG GTA CCT AGG ATC CAG TGT GGT GGA ATT CTG CAG
    Asp Asp Asp Asp Lys Val Pro Arg Ile Gln Cys Gly Gly Ile Leu Gln
    Enterokinase recognition site   EK cleavage site
                                     Asp718 I   Kpn I   BamH I           BstX I*   EcoR I           Pst I
1206 ATA TCC AGC ACA GTG GCG GCC GCT CGA GTC TAG AGGGCCCGTT TAAACCCGCT
    Ile Ser Ser Thr Val Ala Ala Ala Arg Val ***
    EcoR V           BstX I*   Not I           Xho I           Xba I           Apa I
1259 GATCAGCCTC GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC TCCCCCGTGC
                                     BGH reverse priming site

```

*Please note that there are two BstX I sites in the polylinker.

continued on next page

Cloning into pcDNA™ 4/HisMax A, B, and C, continued

Multiple Cloning Site of Version B

Below is the multiple cloning site for pcDNA™ 4/HisMax B. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotides indicate the variable region. The multiple cloning site has been confirmed by sequencing and functional testing. **The complete sequence of pcDNA™ 4/HisMax B is available for downloading from our website (www.lifetechnologies.com) or from Technical Support (see page 19).**

```

821 CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG
                                     T7 promoter/priming site
881 GGAGACCCAA GCTGGCTAGC GTTTAAACTT AAGCTTAGCG CAGAGGCTTG GGCAGCCGA
                                     QBI SP163 translational enhancer
941 GCGGCAGCCA GGCCCCGCC CGGGCCTCGG TTCCAGAAGG GAGAGGAGCC CGCCAAGGCC
1001 CGCAAGAGAG CGGGCTGCCT CGCAGTCCGA GCCGGAGAGG GAGCGCGAGC CGCGCCGGCC
                                     Polyhistidine Region
1061 CCGGACGGCC TCCGAAACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT
    Met Gly Gly Ser His His His His His His His
                                     Xpress™ Epitope
1110 GGT ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC
    Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr
1158 GAC GAT GAC GAT AAG GTA CCT AAG GAT CCA GTG TGG TGG AAT TCT GCA
    Asp Asp Asp Asp Lys Val Pro Lys Asp Pro Val Trp Trp Asn Ser Ala
    Enterokinase recognition site ▲ EK cleavage site
1206 GAT ATC CAG CAC AGT GGC GGC CGC TCG AGT CTA GAG GGC CCG TTT AAA
    Asp Ile Gln His Ser Gly Gly Arg Ser Ser Leu Glu Gly Pro Phe Lys
                                     BGH reverse priming site
1254 CCC GCT GAT CAG CCT CGA CTG TGC CTT CTA GTT GCC AGC CAT CTG TTG
    Pro Ala Asp Gln Pro Arg Leu Cys Leu Leu Val Ala Ser His Leu Leu
1302 TTT GCC CCT CCC CCG TGC CTT CCT TGA CCCTGGAAGG TGCCACTCCC
    Phe Ala Pro Pro Pro Cys Leu Pro ***

```

*Please note that there are two *BstX I* sites in the polylinker.

continued on next page

Cloning into pcDNA™ 4/HisMax A, B, and C, continued

Multiple Cloning Site of Version C

Below is the multiple cloning site for pcDNA™ 4/HisMax C. Restriction sites are labeled to indicate the cleavage site. The boxed nucleotide indicates the variable region. The multiple cloning site has been confirmed by sequencing and functional testing. **The complete sequence of pcDNA™ 4/HisMax C is available for downloading from our website (www.lifetechnologies.com) or from Technical Support (see page 19).**

```

821 CTGGCTAACT AGAGAACCCA CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG
                                     T7 promoter/priming site
881 GGAGACCCAA GCTGGCTAGC GTTTAAACTT AAGCTTAGCG CAGAGGCTTG GGCAGCCGA
                                     QBI SP163 translational enhancer
941 GCGGCAGCCA GGCCCCGGCC CGGGCCTCGG TTCCAGAAGG GAGAGGAGCC CGCCAAGGCC
1001 CGCAAGAGAG CGGGCTGCCT CGCAGTCCGA GCCGGAGAGG GAGCGCGAGC CGCGCCGGCC
1061 CCGGACGGCC TCCGAAACC ATG GGG GGT TCT CAT CAT CAT CAT CAT CAT
    Met Gly Gly Ser His His His His His His
                                     Polyhistidine Region
1110 GGT ATG GCT AGC ATG ACT GGT GGA CAG CAA ATG GGT CGG GAT CTG TAC
    Gly Met Ala Ser Met Thr Gly Gly Gln Gln Met Gly Arg Asp Leu Tyr
                                     Xpress™ Epitope
1158 GAC GAT GAC GAT AAG GTA CCA GGA TCC AGT GTG GTG GAA TTC TGC AGA
    Asp Asp Asp Asp Lys Val Pro Gly Ser Ser Val Val Glu Phe Cys Arg
    Enterokinase recognition site ▲ EK cleavage site
1206 EcoRV      BstX I*    Not I     Xho I     Xba I     Apa I
    TAT CCA GCA CAG TGG CGG CCG CTC GAG TCT AGA GGG CCC GTT TAA
    Tyr Pro Ala Gln Trp Arg Pro Leu Glu Ser Arg Gly Pro Val ***
                                     BGH reverse priming site
1251 ACCCGCTGAT CAGCCTCGAC TGTGCCTTCT AGTTGCCAGC CATCTGTTGT TTGCCCTCC

```

*Please note that there are two *BstX I* sites in the polylinker.

continued on next page

Cloning into pcDNA[™] 4/HisMax A, B, and C, continued

E. coli **Transformation**

Transform your ligation mixtures into a competent *recA*, *endA* *E. coli* strain (e.g. TOP10F', DH5 α [™]) and select on LB plates containing 50-100 μ g/ml ampicillin or 25-50 μ g/ml Zeocin[™] in Low Salt LB medium (see the following section). Select 10-20 clones and analyze for the presence and orientation of your insert.

Low Salt LB **Medium with** **Zeocin[™]**

For Zeocin[™] to be active, the salt concentration of the medium must be low (< 90 mM) and the pH must be 7.5. For selection in *E. coli*, it is **imperative** that you prepare LB broth and plates using the following recipe. Please note the lower salt content of this medium. Failure to use low salt LB medium will result in non-selection due to inactivation of the drug.

Low Salt LB Medium:

10 g Tryptone

5 g NaCl

5 g Yeast Extract

1. Combine the dry reagents above and add deionized, distilled water to 950 ml. Adjust pH to 7.5 with 5 M NaOH. Bring the volume up to 1 liter. For plates, add 15 g/L agar before autoclaving.
 2. Autoclave on liquid cycle at 15 lbs/sq. in. and 121°C for 20 minutes.
 3. Thaw Zeocin[™] on ice and vortex before removing an aliquot.
 4. Allow the medium to cool to at least 55°C before adding the Zeocin[™] to 25 μ g/ml final concentration.
 5. Store plates at 4°C in the dark. Plates containing Zeocin[™] are stable for 1-2 weeks.
-

Important

Any *E. coli* strain that contains the complete Tn5 transposable element (i.e. DH5 α F1Q[™], SURE, SURE2) encodes the *ble* gene (bleomycin resistance gene). These strains will confer resistance to Zeocin[™]. For the most efficient selection, we recommend an *E. coli* strain that does not contain the Tn5 gene (i.e. TOP10, DH5 α [™], DH10, etc.).



We recommend that you sequence your construct with the T7 Forward and BGH Reverse primers (Catalog nos. N560-02 and N575-02, respectively) to confirm that your gene is fused in frame with the N-terminal polyhistidine tag and the Xpress[™] epitope. Please note that if you use the T7 Forward primer to sequence your insert, approximately 300 bp of sequence encoding the QBI SP163 element and the N-terminal tag will precede the sequence of your insert.

Preparing a **Glycerol Stock**

Once you have identified the correct clone, be sure to purify the colony and make a glycerol stock for long-term storage. It is also a good idea to keep a DNA stock of your plasmid at -20°C in case you lose the glycerol stock.

- Streak the original colony out on an LB plate containing 50 μ g/ml ampicillin or 25 μ g/ml Zeocin[™] in Low Salt LB. Incubate the plate at 37°C overnight.
 - Isolate a single colony and inoculate into 1-2 ml of LB containing 50 μ g/ml ampicillin or 25 μ g/ml Zeocin[™].
 - Grow the culture to mid-log phase (OD₆₀₀ = 0.5-0.7).
 - Mix 0.85 ml of culture with 0.15 ml of sterile glycerol and transfer to a cryovial.
 - Store at -80°C.
-

Transfection and Analysis

Introduction

Once you have confirmed that your construct is in the correct orientation and fused in frame with the N-terminal peptide, you are ready to transfect your cell line of choice. We recommend that you include the positive control vector and a mock transfection (negative control) to evaluate your results.

Plasmid Preparation

Plasmid DNA for transfection into eukaryotic cells must be very clean and free from phenol and sodium chloride. Contaminants will kill the cells, and salt will interfere with lipids, decreasing transfection efficiency. We recommend isolating plasmid DNA using the S.N.A.P.[™] MiniPrep Kit (10-15 µg DNA, Catalog no. K1900-01), the S.N.A.P.[™] MidiPrep Kit (10-200 µg DNA, Catalog no. K1910-01), or CsCl gradient centrifugation.

Methods of Transfection

For established cell lines (e.g. HeLa), please consult original references or the supplier of your cell line for the optimal method of transfection. We recommend that you follow exactly the protocol for your cell line. Pay particular attention to medium requirements, when to pass the cells, and at what dilution to split the cells. Further information is provided in *Current Protocols in Molecular Biology* (Ausubel *et al.*, 1994).

Methods for transfection include calcium phosphate (Chen and Okayama, 1987; Wigler *et al.*, 1977), lipid-mediated (Felgner *et al.*, 1989; Felgner and Ringold, 1989) and electroporation (Chu *et al.*, 1987; Shigekawa and Dower, 1988). Life Technologies offers the Calcium Phosphate Transfection Kit (Catalog no. K2780-01) and a large selection of reagents for transfection. Please refer to our website (www.lifetechnologies.com) or call Technical Support (see page 19) for more information.

Positive Control

pcDNA[™] 4/HisMax/*lacZ* is provided as a positive control vector for mammalian cell transfection and expression (see page 18) and may be used to optimize transfection conditions for your cell line. The gene encoding β-galactosidase is expressed in mammalian cells under the control of the CMV promoter. A successful transfection will result in β-galactosidase expression that can be easily assayed (see next page).

continued on next page

Transfection and Analysis, continued

Assay for β -galactosidase Activity

You may assay for β -galactosidase expression by activity assay using cell-free lysates (Miller, 1972) or by staining the cells for activity. Life Technologies offers the β -Gal Assay Kit (Catalog no. K1455-01) and the β -Gal Staining Kit (Catalog no. K1465-01) for fast and easy detection of β -galactosidase expression.

Detection of Fusion Proteins

The Anti-Xpress™ antibodies and the Anti-HisG antibodies are available from Life Technologies to detect expression of your fusion protein from pcDNA™4/HisMax (see page 2).

To detect the fusion protein by western blot, you will need to prepare a cell lysate from transfected cells. We recommend that you perform a time course to optimize expression of the fusion protein (*e.g.* 24, 48, 72 hours, etc. after transfection). To lyse cells:

1. Wash cell monolayers ($\sim 10^6$ cells) once with phosphate-buffered saline (PBS).
 2. Scrape cells into 1 ml PBS and pellet the cells at 1,500 x g for 5 minutes.
 3. Resuspend in 50 μ l Cell Lysis Buffer (see recipe below). Other cell lysis buffers are suitable.
 4. Incubate cell suspension at 37°C for 10 minutes to lyse the cells. **Note:** You may prefer to lyse the cells at room temperature or on ice if degradation of your protein is a potential problem.
 5. Centrifuge the cell lysate at 10,000 x g for 10 minutes to pellet nuclei and transfer the supernatant to a fresh tube. Assay the lysate for protein concentration. **Note:** Do not use protein assays utilizing Coomassie Blue or other dyes. NP-40 interferes with the binding of the dye with the protein.
 6. Add SDS-PAGE sample buffer to a final concentration of 1X and boil the sample for 5 minutes.
 7. Load 20 μ g of lysate onto an SDS-PAGE gel and electrophorese. Use the appropriate percentage of acrylamide to resolve your fusion protein.
-

Cell Lysis Buffer

50 mM Tris-HCl, pH 7.8

150 mM NaCl

1% Nonidet P-40

1. This solution can be prepared from the following common stock solutions. For 100 ml, combine:

1 M Tris base 5 ml

5 M NaCl 3 ml

Nonidet P-40 1 ml

2. Bring the volume up to 90 ml with deionized water and adjust the pH to 7.8 with HCl.
3. Bring the volume up to 100 ml. Store at room temperature.

Note: Protease inhibitors may be added at the following concentrations:

1 mM PMSF

1 μ g/ml pepstatin

1 μ g/ml leupeptin

continued on next page

Transfection and Analysis, continued

Note

The N-terminal peptide containing the Xpress™ epitope and the polyhistidine tag will add approximately 3.4 kDa to the size of your protein. Please note that the QBI SP163 element is **not** translated.

Purification

You will need 5×10^6 to 1×10^7 **transfected** cells for purification of your protein on a 2 ml ProBond™ column (or other metal-chelating column). Please refer to the manufacturer's instructions before attempting to purify your fusion protein. To prepare cells for lysis, please refer to the protocol on page 15.

Creation of Stable Cell Lines

Introduction

The pcDNA™ 4/HisMax vectors contain the Zeocin™ resistance gene for selection of stable cell lines using Zeocin™. We recommend that you test the sensitivity of your mammalian host cell to Zeocin™ as natural resistance varies among cell lines. General information and guidelines are provided in this section for your convenience.


Zeocin™

Zeocin™ is a member of the bleomycin/phleomycin family of antibiotics isolated from *Streptomyces*. Antibiotics in this family are broad spectrum antibiotics that act as strong anti-bacterial and anti-tumor drugs. They show strong toxicity against bacteria, fungi (including yeast), plants, and mammalian cells (Baron *et al.*, 1992; Drocourt *et al.*, 1990; Mulsant *et al.*, 1988; Perez *et al.*, 1989).

The Zeocin™ resistance protein has been isolated and characterized (Calmels *et al.*, 1991; Drocourt *et al.*, 1990). This protein, the product of the *Sh ble* gene (*Streptoalloteichus hindustanus* bleomycin gene), is a 13.7 kDa protein that binds Zeocin™ and inhibits its DNA strand cleavage activity. Expression of this protein in eukaryotic and prokaryotic hosts confers resistance to Zeocin™.

Molecular Weight, Formula, and Structure

The formula for Zeocin™ is $C_{60}H_{89}N_{21}O_{21}S_3$ and the molecular weight is 1,535. The diagram below shows the structure of Zeocin™.



continued on next page

Creation of Stable Cell Lines, continued

Applications of Zeocin™

Zeocin™ is used for selection in mammalian cells (Mulsant *et al.*, 1988); plants (Perez *et al.*, 1989); yeast (Baron *et al.*, 1992); and prokaryotes (Drocourt *et al.*, 1990). Suggested concentrations of Zeocin™ for selection in mammalian cell lines and *E. coli* are listed below:

Organism	Zeocin™ Concentration and Selective Medium
<i>E. coli</i>	25-50 µg/ml in low salt LB medium* (see page 8 for recipe)
Mammalian Cells	50-1000 µg/ml (varies with cell line)

*Efficient selection requires that the concentration of NaCl be no more than 5 g/liter (< 90 mM).

Handling Zeocin™

- High salt and acidity or basicity inactivate Zeocin™. Therefore, we recommend that you reduce the salt in bacterial medium and adjust the pH to 7.5 to keep the drug active (see page 8).
 - Store Zeocin™ at -20°C and thaw on ice before use.
 - Zeocin™ is light sensitive. Store drug, plates, and medium containing drug in the dark.
 - Wear gloves, a laboratory coat, and safety glasses or goggles when handling solutions containing Zeocin™.
 - Zeocin™ is toxic. Do not ingest or inhale solutions containing the drug.
-

Ordering Information

Zeocin™ can be purchased from Life Technologies. For your convenience, the drug is prepared in autoclaved, deionized water and available in 1.25 ml aliquots at a concentration of 100 mg/ml. The stability of Zeocin™ is guaranteed for six months, if stored at -20°C.

Amount	Catalog no.
1 gram	R250-01
5 grams	R250-05

Effect of Zeocin™ on Sensitive and Resistant Cells

Zeocin™'s method of killing is quite different from neomycin and hygromycin. **Cells do not round up and detach from the plate.** Sensitive cells may exhibit the following morphological changes upon exposure to Zeocin™:

- Vast increase in size (similar to the effects of cytomegalovirus infecting permissive cells)
- Abnormal cell shape
- Presence of large empty vesicles in the cytoplasm (breakdown of the endoplasmic reticulum and golgi apparatus, or other scaffolding proteins)
- Breakdown of plasma and nuclear membrane (appearance of many holes in these membranes)

Eventually, these "cells" will completely break down and only cellular debris will remain.

Zeocin™-resistant cells should continue to divide at regular intervals to form distinct colonies. There should not be any distinct morphological changes in Zeocin™-resistant cells when compared to cells not under selection with Zeocin™.

continued on next page

Creation of Stable Cell Lines, continued

Selection in Mammalian Cell Lines

To generate a stable cell line expressing your protein, you need to determine the minimum concentration of Zeocin™ required to kill your untransfected host cell line. In general, concentrations ranging from 50 to 1000 µg/ml Zeocin™ are sufficient to kill the untransfected host cell line, with the average being 250 to 400 µg/ml. Test a range of concentrations to ensure that you determine the minimum concentration necessary for your cell line.

- Seed cells (20-25% confluent) for each time point and allow cells to adhere overnight.
- The next day, substitute culture medium with medium containing varying concentrations of Zeocin™ (e.g. 0, 50, 100, 200, 400, 600, 800, and 1000 µg/ml).
- Replenish the selective medium every 3-4 days, and observe the percentage of surviving cells.
- Count the number of viable cells at regular intervals to determine the appropriate concentration of Zeocin™ that prevents growth. Select the concentration that kills the majority of the cells in the desired number of days (4-10 days).

Possible Sites for Linearization

To obtain stable transfectants, you may choose to linearize your vector before transfection. While linearizing your vector may not improve the efficiency of transfection, it increases the chances that the vector does not integrate in a way that disrupts the gene of interest. The table below lists unique sites that may be used to linearize your construct prior to transfection. **Other restriction sites are possible. Please note that for the enzymes listed below, the cleavage site is indicated for versions A, B, and C of pcDNA™ 4/HisMax.** Be sure that your insert does not contain the restriction enzyme site you wish to use to linearize your vector.

Enzyme	Restriction Site (bp) (A,B,C)	Location	Supplier
<i>Bgl</i> II	12	Upstream of CMV promoter	Many
<i>Mfe</i> I	161	Upstream of CMV promoter	New England Biolabs
<i>Nru</i> I	208	Upstream of CMV promoter	Many
<i>Bst</i> 1107 I	3063 (A), 3064 (B), 3062 (C)	End of SV40 poly A	AGS*, Fermentas, Takara, Boehringer-Mannheim
<i>Eam</i> 1105 I	4335 (A), 4336 (B), 4334 (C)	Ampicillin gene	AGS*, Fermentas, Takara
<i>Fsp</i> I	4557 (A), 4558 (B), 4556 (C)	Ampicillin gene	Many
<i>Pvu</i> I	4705 (A), 4706 (B), 4704 (C)	Ampicillin gene	Many
<i>Sca</i> I	4815 (A), 4816 (B), 4814 (C)	Ampicillin gene	Many
<i>Ssp</i> I	5139 (A), 5140 (B), 5138 (C)	Backbone	Many

*Angewandte Gentechnologie Systeme

continued on next page

Creation of Stable Cell Lines, continued

Selection Tip

Some cells may be more resistant to Zeocin™ than others. If cells are dividing rapidly, Zeocin™ may not be effective at low concentrations. To overcome this resistance, we recommend that you place the cells at +4°C for 2 hours after plating (be sure to buffer the medium with HEPES). Then return the cells to 37°C. This will stop the cell division process for a short time and allow Zeocin™ to act.

Selection of Stable Integrants

Once the appropriate Zeocin™ concentration is determined, you can generate a stable cell line with your construct.

- Transfect your cells using the appropriate protocol for your cell line. Include a sample of untransfected cells as a negative control.
 - After transfection, wash the cells once with 1X PBS and add fresh medium to the cells.
 - 48 hours after transfection, split the cells into fresh medium containing Zeocin™ at the appropriate concentration for your cell line. Split the cells such that they are no more than 25% confluent.
 - Replenish selective medium every 3-4 days until Zeocin™-resistant colonies are detected.
 - Pick and expand colonies in 96- or 48-well plates. Grow cells to near confluence before expanding to larger wells or plates.
-

Preparation of Cells for Lysis

Use the procedure below to prepare cells for lysis prior to purification of your protein on ProBond™. You will need 5×10^6 to 1×10^7 cells for purification of your protein on a 2 ml ProBond™ column (see ProBond™ Purification System manual).

1. Seed cells in either five T-75 flasks or 2 to 3 T-175 flasks.
 2. Grow the cells in selective medium until they are 80-90% confluent.
 3. Harvest the cells by treating with trypsin-EDTA for 2 to 5 minutes or by scraping the cells in PBS.
 4. Inactivate the trypsin by diluting with fresh medium (if necessary) and transfer the cells to a sterile microcentrifuge tube.
 5. Centrifuge the cells at 1500 rpm for 5 minutes. Resuspend the cell pellet in PBS.
 6. Centrifuge the cells at 1500 rpm for 5 minutes. Remove PBS. You may lyse the cells immediately or freeze in liquid nitrogen and store at -70°C until needed.
-

Lysis of Cells

If you are using ProBond™ resin, please refer to the ProBond™ Purification System manual for details about sample preparation for chromatography.


If you are using other metal-chelating resin, please refer to the manufacturer's instruction for recommendations on sample preparation.

Appendix

pcDNA™ 4/HisMax Vector

Map of pcDNA™ 4/HisMax

The figure below summarizes the features of the pcDNA™ 4/HisMax vectors. The sequences for pcDNA™ 4/HisMax A, B, and C are available for downloading from our website (www.lifetechnologies.com) or from Technical Support (see page 19).



Comments for pcDNA4/HisMax[®] A: 5258 nucleotides

- CMV promoter: bases 232-819
- T7 promoter/priming site: bases 863-882
- QBI SP163 translational enhancer: bases 917-1079
- ATG initiation codon: bases 1080-1082
- Polyhistidine tag: bases 1092-1109
- Xpress™ epitope: bases 1149-1172
- Enterokinase recognition site: bases 1158-1172
- Multiple cloning site: bases 1172-1245
- BGH reverse priming site: bases 1265-1282
- BGH polyadenylation sequence: bases 1268-1495
- f1 origin: bases 1541-1969
- SV40 promoter and origin: bases 1996-2305
- EM-7 promoter: bases 2353-2408
- Zeocin™ resistance gene: bases 2427-2801
- SV40 polyadenylation sequence: bases 2931-3061
- pUC origin: bases 3444-4117
- Ampicillin resistance gene: bases 4262-5122

* There is a stop codon following the Xba I site in version A.

continued on next page

pcDNA™ 4/HisMax Vector, continued

Features of pcDNA™ 4/HisMax

pcDNA™ 4/HisMax A (5258 bp), pcDNA™ 4/HisMax B (5259 bp), and pcDNA™ 4/HisMax C (5257 bp) contain the following elements. All features have been functionally tested.

Feature	Benefit
Human cytomegalovirus (CMV) immediate-early promoter/enhancer	Allows efficient, high-level expression of your recombinant protein (Andersson <i>et al.</i> , 1989; Boshart <i>et al.</i> , 1985; Nelson <i>et al.</i> , 1987)
T7 promoter/priming site	Allows for <i>in vitro</i> transcription in the sense orientation and sequencing through the insert
QBI SP163 translational enhancer	Increases expression of your recombinant protein via a cap-independent translation mechanism (Stein <i>et al.</i> , 1998)
N-terminal polyhistidine tag	Allows purification of your recombinant protein on metal-chelating resin such as ProBond™
Xpress™ epitope tag	Allow detection of your recombinant protein with the Anti-Xpress™ Antibody (Catalog no. R910-25)
Enterokinase cleavage site	Allows removal of the N-terminal tag from your recombinant protein using an enterokinase such as EnterokinaseMax™ (Catalog no. E180-01)
Multiple cloning site in three reading frames	Allows insertion of your gene and facilitates cloning in frame with the Xpress™ epitope and N-terminal polyhistidine tag
BGH reverse priming site	Allows sequencing through the insert
Bovine growth hormone (BGH) polyadenylation signal	Efficient transcription termination and polyadenylation of mRNA (Goodwin and Rottman, 1992)
f1 origin	Allows rescue of single-stranded DNA
SV40 early promoter and origin	Allows efficient, high-level expression of the Zeocin™ resistance gene in mammalian cells and episomal replication in cells expressing the SV40 large T antigen
EM-7 promoter	Synthetic promoter based on the bacteriophage T7 promoter for expression of the Zeocin™ resistance gene in <i>E. coli</i>
Zeocin™ resistance gene	Selection of transformants in <i>E. coli</i> and stable transfectants in mammalian cells (Drocourt <i>et al.</i> , 1990; Mulsant <i>et al.</i> , 1988)
SV40 polyadenylation signal	Efficient transcription termination and polyadenylation of mRNA
pUC origin	High-copy number replication and growth in <i>E. coli</i>
Ampicillin resistance gene (β-lactamase)	Selection of transformants in <i>E. coli</i>


pcDNA™ 4/HisMax//lacZ

Description

pcDNA™ 4/HisMax//lacZ is a 8321 bp control vector containing the gene for β-galactosidase. This vector was constructed by ligating a 3.1 kb *Kpn* I-*Eco*R I fragment containing the *lacZ* gene into the *Kpn* I-*Eco*R I site of pcDNA™ 4/HisMax.

Map of Control Vector

The figure below summarizes the features of the pcDNA™ 4/HisMax//lacZ vector. **The complete nucleotide sequence for pcDNA™ 4/HisMax//lacZ is available for downloading from our website (www.lifetechnologies.com) or from Technical Support (see page 19).**



Comments for pcDNA4/HisMax[®]/lacZ: 8321 nucleotides

CMV promoter: bases 232-819
T7 promoter/priming site: bases 863-882
QBI SP163 translational enhancer: bases 917-1079
ATG initiation codon: bases 1080-1082
Polyhistidine tag: bases 1092-1109
Xpress[™] epitope: bases 1149-1172
Enterokinase recognition site: bases 1158-1172
LacZ ORF: bases 1197-4247
BGH reverse priming site: bases 4328-4345
BGH polyadenylation sequence: bases 4331-4558
f1 origin: bases 4604-5032
SV40 promoter and origin: bases 5059-5368
EM-7 promoter: bases 5416-5471
Zeocin[™] resistance gene: bases 5490-5864
SV40 polyadenylation sequence: bases 5994-6124
pUC origin: bases 6507-7180
Ampicillin resistance gene: bases 7325-8185

Technical Support

Obtaining support For the latest services and support information for all locations, go to www.lifetechnologies.com.

At the website, you can:

- Access worldwide telephone and fax numbers to contact Technical Support and Sales facilities
- Search through frequently asked questions (FAQs)
- Submit a question directly to Technical Support (techsupport@lifetech.com)
- Search for user documents, SDSs, vector maps and sequences, application notes, formulations, handbooks, certificates of analysis, citations, and other product support documents
- Obtain information about customer training
- Download software updates and patches

Safety Data Sheets (SDS)

Safety Data Sheets (SDSs) are available at www.lifetechnologies.com/support.

Certificate of Analysis

The Certificate of Analysis provides detailed quality control and product qualification information for each product. Certificates of Analysis are available on our website. Go to www.lifetechnologies.com/support and search for the Certificate of Analysis by product lot number, which is printed on the box.

Limited warranty

Life Technologies and/or its affiliate(s) warrant their products as set forth in the Life Technologies General Terms and Conditions of Sale found on the Life Technologies web site at <http://www.lifetechnologies.com/termsandconditions>. If you have any questions, please contact Life Technologies.

Life Technologies and/or its affiliate(s) disclaim all warranties with respect to this document, expressed or implied, including but not limited to those of merchantability or fitness for a particular purpose. In no event shall Life Technologies and/or its affiliate(s) be liable, whether in contract, tort, warranty, or under any statute or on any other basis for special, incidental, indirect, punitive, multiple or consequential damages in connection with or arising from this document, including but not limited to the use thereof.

Purchaser Notification

**Limited Use Label
License No. 358:
Research Use
Only**

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

**Limited Use Label
License No. 22:
and Clones
Encoding Histidine
Hexamer**

This product is licensed from Hoffmann-LaRoche, Inc., Nutley, NJ and/or Hoffmann-LaRoche Ltd., Basel, Switzerland and is provided only for use in research. Information about licenses for commercial use is available from QIAGEN GmbH, Max-Volmer-Str. 4, D-40724 Hilden, Germany.

**Limited Use Label
License No. 77:
QBI SP163
Translational
Enhancer**

The QBI SP163 mammalian expression system technology is owned by QBI Enterprises, Ltd. and licensed to Life Technologies. Purchasers of this product are granted a license to use the QBI SP163 mammalian expression system only for internal, research purposes, which license specifically excludes the right to sell, transfer, make, commercialize or otherwise exploit the QBI SP163 mammalian expression system or its component parts. In accepting this license, all users acknowledge that QBI Enterprises, Ltd. makes no warranties, express or implied of any kind, and hereby disclaims any warranties, representations or guarantees of any kind as to the QBI SP163 mammalian expression system product.

All users intending to use the product other than as licensed above are required to obtain a license from QBI Enterprises, Ltd. prior to purchase or use for any such other purpose. Life Technologies is required by its licensing agreement to report to QBI the identity of all purchasers of the SP163 mammalian expression system. Inquiries regarding commercial licenses should be directed to: QBI Enterprises Ltd., Vice-President, Business Development, Weizmann Scientific Park, P.O. Box 741, Nes Ziona 74106, Israel, Tel: 972-8-940-8147, Fax: 972-8-940-6476.

References

- Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989). Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme. *J. Biol. Chem.* *264*, 8222-8229.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1994). *Current Protocols in Molecular Biology* (New York: Greene Publishing Associates and Wiley-Interscience).
- Baron, M., Reynes, J. P., Stassi, D., and Tiraby, G. (1992). A Selectable Bifunctional b-Galactosidase: Phleomycin-resistance Fusion Protein as a Potential Marker for Eukaryotic Cells. *Gene* *114*, 239-243.
- Boshart, M., Weber, F., Jahn, G., Dorsch-Häsler, K., Fleckenstein, B., and Schaffner, W. (1985). A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus. *Cell* *41*, 521-530.
- Calmels, T., Parriche, M., Burand, H., and Tiraby, G. (1991). High Efficiency Transformation of *Tolypocladium geodes* Conidiospores to Phleomycin Resistance. *Curr. Genet.* *20*, 309-314.
- Chen, C., and Okayama, H. (1987). High-Efficiency Transformation of Mammalian Cells by Plasmid DNA. *Mol. Cell. Biol.* *7*, 2745-2752.
- Chu, G., Hayakawa, H., and Berg, P. (1987). Electroporation for the Efficient Transfection of Mammalian Cells with DNA. *Nuc. Acids Res.* *15*, 1311-1326.
- Drocourt, D., Calmels, T. P. G., Reynes, J. P., Baron, M., and Tiraby, G. (1990). Cassettes of the *Streptoalloteichus hindustanus ble* Gene for Transformation of Lower and Higher Eukaryotes to Phleomycin Resistance. *Nuc. Acids Res.* *18*, 4009.
- Felgner, P. L., Holm, M., and Chan, H. (1989). Cationic Liposome Mediated Transfection. *Proc. West. Pharmacol. Soc.* *32*, 115-121.
- Felgner, P. L., and Ringold, G. M. (1989). Cationic Liposome-Mediated Transfection. *Nature* *337*, 387-388.
- Goodwin, E. C., and Rottman, F. M. (1992). The 3'-Flanking Sequence of the Bovine Growth Hormone Gene Contains Novel Elements Required for Efficient and Accurate Polyadenylation. *J. Biol. Chem.* *267*, 16330-16334.
- Miller, J. H. (1972). *Experiments in Molecular Genetics* (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory).
- Mulsant, P., Tiraby, G., Kallerhoff, J., and Perret, J. (1988). Phleomycin Resistance as a Dominant Selectable Marker in CHO Cells. *Somat. Cell Mol. Genet.* *14*, 243-252.
- Nelson, J. A., Reynolds-Kohler, C., and Smith, B. A. (1987). Negative and Positive Regulation by a Short Segment in the 5'-Flanking Region of the Human Cytomegalovirus Major Immediate-Early Gene. *Mol. Cell. Biol.* *7*, 4125-4129.
- Perez, P., Tiraby, G., Kallerhoff, J., and Perret, J. (1989). Phleomycin Resistance as a Dominant Selectable Marker for Plant Cell Transformation. *Plant Mol. Biol.* *13*, 365-373.
- Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*, Second Edition (Plainview, New York: Cold Spring Harbor Laboratory Press).

continued on next page

References, continued

Shigekawa, K., and Dower, W. J. (1988). Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells. *BioTechniques* 6, 742-751.

Stein, I., Itin, A., Einat, P., Skaliter, R., Grossman, Z., and Keshet, E. (1998). Translation of Vascular Endothelial Growth Factor mRNA by Internal Ribosome Entry: Implications for Translation under Hypoxia. *Mol. Cell. Biol.* 18, 3112-3119.

Wigler, M., Silverstein, S., Lee, L.-S., Pellicer, A., Cheng, Y.-C., and Axel, R. (1977). Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells. *Cell* 11, 223-232.

© 2011 Life Technologies Corporation. All rights reserved.

The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

Zeocin is a trademark of CAYLA, SA.

Headquarters

5791 Van Allen Way | Carlsbad, CA 92008 USA | Phone +1 760 603 7200 | Toll Free in USA 800 955 6288

For support visit www.lifetechnologies.com/support or email techsupport@lifetech.com

www.lifetechnologies.com

